Chemotherapy Induced Thrombocytopenia
Conditions
Brief summary
Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a result of a chemotherapy treatment. AS101 is a tellurium based small compound with immunomodulating characteristics which attributed to the direct inhibition of the anti-inflammatory cytokine IL-10. AS101 was previously shown to induce a significant reduction in thrombocytopenia that accompany cancer therapy with no major toxicity . This phase II randomized open study will evaluate the efficacy of AS101 for the treatment of chemotherapy induced thrombocytopenia in patients with various solid tumors.
Interventions
DRUGAS101
intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
Sponsors
BioMAS Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 * Appropriate histology of solid tumors. * Platelet counts \< 70,000/μl. * Performance Status (PS) of 0-2 * Adequate renal function: Serum creatinine ≤1.5 mg/dL * Adequate liver function: Serum (total) bilirubin ≤ 1.5 ULN. AST, ALT ≤ 2.5 x ULN in patients without liver metastases, ≤ 5 x ULN in patients with liver metastases. Albumin ≥ 2.5 g/dL (Only for patients who will receive AS101). * INR ≤ 1.5 and PTT ≤ 1.5 x ULN (Only for patients who will receive AS101).
Exclusion criteria
* Patients unable to provide fully informed consent. * Women who are pregnant or breast feeding. * The patient is participating in another trial of an investigational drug or has done so within 28 days prior to the pre-treatment visit. * The patient has congestive heart failure-New York Heart Association (CHF-NYHA) grade II or higher, and/or myocardial infarction within the last 12 months, or any cardiac disorder which in the opinion of the Investigator would put the patient at risk. * The patient has a history of chronic alcohol or drug abuse within the last 5 years. * The patient has any other clinically significant medical condition, psychiatric condition or laboratory abnormality which would, in the judgment of the Investigator, interfere with the patient's ability to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of thrombocytopenia events (platelets <70,000) over the study period of the study groups | continously during study and 6 months after study termination |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of Safety and tolerability; Thrombocytopenia events that caused treatment delays and chemotherapy dose; reductions; Progression Free Survival (PFS); Response Rate (RR); | continously during study and 6 months after study termination |
Countries
Israel
Outcome results
None listed